Suprachoroidal Administration in Subjects With Metastases to the Choroid
Start Date
12/16/2024
Completion Date
10/31/2027
Summary
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Detailed Description
This is an open-label, dose escalation trial designed to assess safety and tolerability of 4 dose strengths and 1-2 cycles of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
AU-011
SCS Microinjector
Laser
Conditions
Locations
Byers Eye Institute at Stanford University
Palo Alto, California 94303
United States
Bascom Palmer Eye Institute
Miami, Florida 33136
United States
Massachusetts Eye and Ear
Boston, Massachusetts 02114
United States
Kellogg Eye Center
Ann Arbor, Michigan 48105
United States
Mayo Clinic
Rochester, Minnesota 55905
United States
Cleveland Clinic, Cole Eye Institute
Cleveland, Ohio 44195
United States
Shields and Shields, PC
Philadelphia, Pennsylvania 19107
United States
Tennessee Retina, PC
Nashville, Tennessee 37203
United States
Retina Consultants of Texas
Bellaire, Texas 77401
United States
University of Washington
Seattle, Washington 98104
United States